[1]徐颖,徐晓辉.131I治疗甲亢后的继发甲减及替代治疗[J].国际放射医学核医学杂志,2004,28(6):265-266.
　XU Ying,XU Xiao-hui.The secondary hypothyroidism after radioiodine therapy and the replacement treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2004,28(6):265-266.
点击复制

131I治疗甲亢后的继发甲减及替代治疗(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
28
期数:
2004年第6期
页码:
265-266
栏目:
核医学
出版日期:
1900-01-01

文章信息/Info

Title:
The secondary hypothyroidism after radioiodine therapy and the replacement treatment
作者:
徐颖;  徐晓辉
617067 四川攀枝花, 四川省攀枝花市中心医院核医学科
Author(s):
XU Ying;  XU Xiao-hui
Department of Nuclear Medicine, Panzhihua Central Hospital, Sichuan Panzhihua 617067, China
关键词:
甲状腺功能减退症; 碘放射性同位素; 放射治疗; 替代治疗
Keywords:
secondary hypothyroidism; iodine radiosotopes; radiotherapy; replacement treatment
分类号:
R581.2
摘要:
继发性甲状腺功能减退症(甲减)是131I治疗甲状腺功能亢进症(甲亢)后最重要的并发症。早发甲减与晚发甲减的发生机制不尽相同,有待进一步研究。甲减替代治疗是用动物甲状腺提取物还是用L-T3和L-T4复合制剂,目前尚无肯定回答。
Abstract:
The secondary hypothyroidism is the most important intercurrent disease after radioiodine therapy. The early hypothyroidism and the late hypothyroidism are incompletely different in pathogenesis. It needs researching further. There has not yet been an affirmable answer to choose the distillates from animal hypothyroid extract or complex preparation of levo-thyroxine in replacement treatment.

参考文献/References:

1 Gomez JM,Gomez N,Amat M,et al.Hypothyroidism after iodine-131 or surgical therapy for Graves disease hyperthyroidism[J].Ann Endocrinol,2000,61(3):184-191.
2 Sabri O,Zimny M,Schreckenberger M,et al.Determination of factors affecting the therapeutic outcome of radioiodine therapy in patients with Graves disease[J].Nuklearmedizin,1998,37:83-89.
3 Ahmad AM,Ahmad M,Young ET.Objective estimates of the probability of developing hypothyroidism following radioactive iodine treatment of thyrotoxicosis[J].Eur J Endocrinol,2002,1!6(6):767-775.
4 Yoshida K,Aizawa Y,KaiseN,et al.Role of thyroid-stimulating blocking antibody in patients who developed hypothyroidism withi none year after 131I treatment for Graves disease[J].Clin Endocrinol,1998,48(1):17-22.
5 Mondel SJ,Brent GA,Larsen PR.Levothyroxine theraphy in patients with thyroid disease[J].Ann Intern Med,1993,119:492-499.
6 Apasso G,De Tommaso G,Pica Z,et al.Effects of thyroid hormones on heart and kidney functions[J].Miner Electrolyte Metab,1999,25(1~2):56~64.
7 吴泰相,王家良.碘甲腺氨酸脱碘酶研究进展[J].中华内分泌代谢杂志,2000,16(3):193~195.
8 Buneveclus R,Kazanavicius G,Zalinkevicius R,et al.Effects of thyroxine as compared with thyroxine plus triiodothyronine in patients with hypothyroidism[J].N Engl J Med,1997,126:226-231.

相似文献/References:

[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
　Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]邓艳,张伟.125I-碘酞酸盐临床应用进展[J].国际放射医学核医学杂志,2016,40(3):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
　Deng Yan,Zhang Wei.125I-iothalamate clinical applications[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
[3]田琦,蒋宁一,郑丽.265例精细个体化131I治疗Graves甲亢的疗效观察[J].国际放射医学核医学杂志,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
　Tian Qi,Jiang Ningyi,Zheng Li.Therapeutic effect of fine individual 131I treatment on Graves disease hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
[4]贾强,孟召伟,谭建.异位甲状腺发病机理、诊断与治疗的研究进展[J].国际放射医学核医学杂志,2016,40(4):297.[doi:10.3760/cma.j.issn.1673-4114.2016.04.012]
　Jia Qiang,Meng Zhaowei,Tan Jian.Progress of pathogenisis, diagnosis and treatment of ectopic thyroid[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):297.[doi:10.3760/cma.j.issn.1673-4114.2016.04.012]
[5]杨珂,唐波,于夕荣,等.甲状腺癌131i治疗病房的辐射屏蔽计算与评价[J].国际放射医学核医学杂志,2015,39(5):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
　yang ke,tang bo,yu xirong,et al.shielding calculation and assessment in 131i therapy for thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
[6]刘娇,程兵,常伟,等.非高危分化型甲状腺癌低剂量和高剂量131I清甲疗效的分析[J].国际放射医学核医学杂志,2016,40(6):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
　Liu Jiao,Cheng Bing,Chang Wei,et al.Ablation efficacy in non-high-risk differentiated thyroid carcinoma patients with low-dose and high-dose 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
[7]徐蓉生,梅艳,赵力威,等.B超引导下术中125I粒子植入治疗晚期胰腺癌的疗效评价[J].国际放射医学核医学杂志,2016,40(6):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
　Xu Rongsheng,Mei Yan,Zhao Liwei,et al.Evaluation of 125I particle implantation in the treatment of patients with advanced pancreatic neoplasms using B ultrasound-guided surgery[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
[8]王越,晋建华,李思进,等.甲状腺24h摄碘率与131I治疗Graves甲亢疗效相关性研究[J].国际放射医学核医学杂志,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
　Wang Yue,Jin Jianhua,Li Sijin,et al.Correlation between thyroid 24 h of radioactive iodine uptake and clinical efficacy of 131I therapy for Graves’ hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
[9]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
　Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[10]赵腾,梁军,林岩松.131I治疗前刺激性Tg在分化型甲状腺癌风险评估及治疗决策中的意义[J].国际放射医学核医学杂志,2015,39(1):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
　Zhao Teng,Liang Jun,Lin Yansong.The role of preablative stimulated thyroglobulin in guiding risk estimation and therapeutic decisions of differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
[11]陈雪梅,周树云,范源,等.表没食子儿茶素没食子酸酯对131I辐射损伤所致甲减大鼠模型抗氧化体系的保护作用[J].国际放射医学核医学杂志,2015,39(4):311.[doi:10.3760/cma.j.issn.1673-4114.2015.04.009]
　Chen Xuemei,Zhou Shuyun,Fan Yuan,et al.Protection of antioxidant system of EGCG on the thyroid in rat model from 131I radiation damage[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):311.[doi:10.3760/cma.j.issn.1673-4114.2015.04.009]
[12]李诗运,谭本旭,戴儒奇,等.优甲乐和稳定性碘干预131I致大鼠甲状腺功能减低的研究[J].国际放射医学核医学杂志,2007,31(6):325.
　LI Shi-yun,TAN Ben-xu,DAI Ru-qi,et al.Interventions of euthyrox and stable iodine in hypothyroid occurrence of rats treated with 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(6):325.
[13]陈再君,蒋宁一.131I治疗甲亢后致甲减的研究变迁[J].国际放射医学核医学杂志,2004,28(4):153.
　CHEN Zai-jun,JIANG Ning-yi.The research vicissitudes of hypothyroidism after 131I therapy for hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2004,28(6):153.
[14]李诗运.131I治疗甲亢后甲减的综合预防和处理措施[J].国际放射医学核医学杂志,2004,28(4):157.
　LI Shi-yun.Synthetic prevention and treatment for hypothyroidism after rdioiodine therapy hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2004,28(6):157.

备注/Memo

备注/Memo:
收稿日期:2004-04-13。
更新日期/Last Update: 1900-01-01